Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1412 • 2017 ACR/ARHP Annual Meeting
Yra-1909 suppresses Production of Pro-Inflammatory Mediators and MMPs through Downregulating Akt, p38, JNK and NF-κb Activation in Rheumatoid Arthritis Fibroblast-like Synoviocytes
Hyun Jung Yoo^1,2, Jeong Yeon Kim¹, Shin Eui Kang¹, Ji Seok Yoo³, Yong Nam Lee³, Dong Goo Lee³, Ji Soo Park¹, Eun Bong Lee⁴, Eun Young Lee⁴ and Yeong Wook Song^2,5, ¹Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Seoul, Korea, Republic of (South), ³Central R&D Institute, Yungjin Pharm Co., Ltd., Suwon, Korea, Suwon, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ⁵Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, Republic of (South)
Background/Purpose: Rheumatoid arthritis (RA) is characterized by hyperplastic synovial pannus tissue, which mediates destruction of cartilage and bone. Fibroblast-like synoviocyte (FLS) are a key component…
Abstract Number: 1940 • 2017 ACR/ARHP Annual Meeting
Immunologic Synovitis Score: A New Score for Synovial Membrane Characterization in Inflammatory and Non-Inflammatory Arthritis
Aurélie Najm^1,2, Benoît Le Goff MD PhD^2,3, Frédéric Blanchard¹, Jérome Amiaud⁴, Céline Charrier⁵ and Veit Krenn⁶, ¹INSERM U1238 University of medicine, PHY-OS Laboratory, Nantes, France, ²Rheumatology, Nantes University Hospital, Nantes, France, ³UNR1238 University of medicine, PHY-OS Laboratory, Nantes, France, ⁴UMR1238 University of medicine, PHY-OS Laboratory, Nantes, France, ⁵UNMR1238 University of medicine, PHY-OS Laboratory, Nantes, France, ⁶Zytologie und Molekulare Diagnostik, MVZ-Zentrum für Histologie, Trier, Germany
Background/Purpose: General Synovitis score (GSS) has been developed by Krenn et al in order to discriminate inflammatory arthritis (IA) and non-inflammatory arthritis (NIA) (1). This…
Abstract Number: 2436 • 2017 ACR/ARHP Annual Meeting
MiR-146a Upregulates the TLR4/NF-κb Signaling Pathway to Promote Cytokine Expression and Synovial Fibroblast Proliferation in Rheumatoid Arthritis
Yuan-hao Wu^1,2, Wei Liu¹, Lei Zhang³, Bin Xue³, Yi Wang³, Xiao-ya Liu³, Yang Ji⁴, Ran Duan³, Yue Cai³ and Bo Zhang³, ¹Department of Rheumatology and Immunology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China, ²Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China, ³First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China, ⁴The 272nd Hospital of Chinese People's Liberation Army, Tianjin, China
Background/Purpose: To investigate the role of miR-146a in the activation of toll-like receptor-4 (TLR4)/ nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway, and…
Abstract Number: 2704 • 2017 ACR/ARHP Annual Meeting
Skin Migratory Dendritic Cells Targeted and Tolerized By Calcitriol-Peptide Liposomes Supress Antigen-Specific Autoreactive T Cell Expansion and Memory Differentiation to Regulate Autoimmune Arthritis
Ryan Galea^1,2, Hendrik Nel^1,2, Meghna Talekar^1,2, Suzanne Cole³, Karyn Cochlin⁴, Shannon Hitchcock⁵, Bijun Zeng^1,2, Suman Yekollu^1,2, Jamie Rossjohn⁶, Hugh Reid⁷, Ravi Malaviya⁵, Dave Shealy⁸, Brendan O'Sullivan^1,2 and Ranjeny Thomas^1,2, ¹Dendright Pty Ltd, Brisbane, Australia, ²University of Queensland Diamantina Institute, Brisbane, Australia, ³Immunology, Janssen Research and Development, Spring House, PA, ⁴Immunology, Janssen Research and Development, Springhouse, PA, ⁵Janssen Research and Development, Springhouse, PA, ⁶Infection and Immunity Program, Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia, ⁷Monash University, Melbourne, Australia, ⁸Janssen Research and Development, Spring House, PA
Background/Purpose: Current treatments to control autoimmune arthritis and vasculitis use broadly immunosuppressive drugs, associated with undesirable side effects. Antigen-specific immunological tolerance strategies are preferable to…
Abstract Number: 61 • 2017 ACR/ARHP Annual Meeting
Resolution of Systemic Joint Inflammatory Processes and Regeneration of Existing Bone Damage upon TNF Blockade As Monitored By In Vivo Multimodal PET-CT Imaging in Progressed Experimental Arthritis
Silvia Hayer¹, Markus Zeilinger^2,3, Volker Weiss^3,4, Markus Seibt⁵, Birgit Niederreiter¹, Tetyana Shvets⁶, Monika Dumanic⁶, Florian Pichler⁶, Marcus Hacker⁶, Josef S. Smolen⁷, Kurt Redlich⁸ and Markus Mitterhauser⁶, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Faulty of Engineering, University of Applied Sciences, Winer Neustadt, Austria, ³Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, ⁴Faculty of Engineering, University of Applied Sciences, Wiener Neustadt, Austria, ⁵Department Internal Medicine III, Division Rheumatology, Medical University of Vienna, Vienna, Austria, ⁶Medical University of Vienna, Vienna, Austria, ⁷Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ⁸Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: To use in vivo multimodal [18F]FDG (fluoro-D-glucose, tracer for inflammation) and [18F]Sodium Fluoride (bone tracer) positron emission tomography/computed tomography (PET-CT) imaging for the monitoring…
Abstract Number: 2869 • 2017 ACR/ARHP Annual Meeting
Significant Decrease of T-Cells but Not Macrophages in the Synovium of Patients with Active Rheumatoid Arthritis after Treatment with Tocilizumab
Katerina Chatzidionysiou¹, Marianne Engström¹, Erik af Klint¹, Aase Hensvold¹ and Anca I Catrina², ¹Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ²Department of Medicine, Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Tocilizumab (TCZ) is an anti-IL6R monoclonal antibody approved for the treatment of Rheumatoid Arthritis (RA). There is limited data on synovial tissue histology changes.…
Abstract Number: 171 • 2017 ACR/ARHP Annual Meeting
Finding Transcriptional Regulators Central to RA with Transcriptomics of IL17 Dose Response, Time Series, and siRNA Silencing in Stromal Cells
Kamil Slowikowski¹, Hung Nguyen², Gerald Watts², Fumitaka Mizoguchi³, Erika H. Noss⁴, Michael Brenner⁵ and Soumya Raychaudhuri⁶, ¹Harvard University, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ⁴Division of Rheumatology, University of Washington, Seattle, WA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is characterized by immune cell infiltration into the synovial membrane of the joint, where they engage stromal cells such as synovial…
Abstract Number: 2913 • 2017 ACR/ARHP Annual Meeting
the Periodontal Pathogen Aggregatibacter Actinomycetemcomitans Is Associated with Subclinical Coronary Atherosclerosis in Rheumatoid Arthritis
Jon T. Giles¹, Jesper Reinholdt², Joan Bathon³, Felipe Andrade⁴ and Maximilian F. Konig⁵, ¹Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, NY, ²Department of Biomedicine, Aarhus University, Aarhus, Denmark, ³Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ⁴Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The oral pathogen Aggregatibacter actinomycetemcomitans (Aa) generates citrullinated proteins targeted by autoantibodies in RA through its pore-forming toxin leukotoxin A (LtxA). Aa-derived LtxA is…
Abstract Number: 394 • 2017 ACR/ARHP Annual Meeting
Female Tumor Necrosis Factor Transgenic Mice Have More Severe Arthritis Than Males and Supporessed Levels of Bifidobacterium Pseudolongum in Their Gut Microbiome
Emily Wu¹, Richard Bell², Alex Grier³, Steven Gill⁴, Edward Schwarz⁵ and Homaira Rahimi⁶, ¹Department of Immunology, Microbiology, and Virology, University of Rochester, Rochester, NY, ²Center for Musculoskelatal Research, University of Rochester, Rochester, NY, ³Rochester Genomics Center, University of Rochester, Rochester, NY, ⁴Genomics Research Center, University of Rochester, Rochester, NY, ⁵Orthopedeatrics, University of Rochester, Rochester, NY, ⁶Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY
Background/Purpose: Rheumatoid arthritis (RA) has an increased prevalence and severity in women compared to men, yet the underlying etiology of this sexual dimorphism is unknown.…
Abstract Number: 2963 • 2017 ACR/ARHP Annual Meeting
Sirukumab Improves Synovial Vascularity As Measured By Power Doppler Sonography in Rheumatoid Arthritis Patients from As Early As Week 4 in a Phase 3 Trial
Bidisha Dasgupta¹, Kristen Sweet¹, Dick DeVries², Benjamin Hsu¹, Ian Gourley¹, Matthew Loza¹ and Peter C. Taylor³, ¹Janssen Research & Development, LLC, Spring House, PA, ²Janssen Biologics Europe, Leiden, Netherlands, ³Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom
Background/Purpose: Ultrasound (US) is an established non-invasive tool for sensitively assessing disease activity at the individual‐joint level in rheumatoid arthritis (RA). Synovial thickness is detectable…
Abstract Number: 395 • 2017 ACR/ARHP Annual Meeting
Pharmacological and Safety Profiles of Cyclin-Dependent Kinase 4/6 Inhibitor, Candidate for Development As Rheumatoid Arthritis Therapeutic Option
Johji Nomura¹, Shunsuke Tsujimoto², Kei Tamura², Wataru Yamamoto², Hiroshi Takahashi², Kyohei Horie², Toshiya Mashiko², Naoki Hase² and Tsunefumi Kobayashi², ¹Teijin Institute for Bio-medical Research, TEIJIN PHARMA LIMITED, Tokyo, Japan, ²TEIJIN PHARMA LIMITED, Tokyo, Japan
Background/Purpose: The pathogenesis of rheumatoid arthritis (RA) is characterized by the infiltration of immune cells into the synovial tissues and the excessive proliferation of synovial…
Abstract Number: 396 • 2017 ACR/ARHP Annual Meeting
Phospho-STAT1 Inhibition Is the Initial Step after Tofacitinib Treatment in Rabbits with Severe Chronic Synovitis
Sandra Pérez-Baos, Paula Gratal, Juan Ignacio Barrasa, Ana Lamuedra, Gabriel Herrero-Beaumont and Raquel Largo, Bone and Joint Research Unit, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain
Background/Purpose: Tofacitinib (TOFA) is a Janus Kinase (Jak) inhibitor approved for the treatment of rheumatoid arthritis (RA) 1. It has recently been shown to selectively…
Abstract Number: 398 • 2017 ACR/ARHP Annual Meeting
An on-Demand Drug Delivery System for the Treatment of Inflammatory Arthritis
Jing Yan¹, Nitin Joshi², Seth Levy², Sachin Bhagchandani², Kai Slaughter², Nicholas Sherman¹, Julian Amirault², Xueyin He², Tan Shi Rui², Michael Valic², Praveen Vemula³, Oscar Miranda², Oren Levy², Antonios Aliprantis⁴, Joerg Ermann¹ and Jeffrey Karp², ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Institute for Stem Cell Biology and Regenerative Medicine (inStem), Bangalore, India, ⁴Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Many types of inflammatory arthritis (IA) are treated with systemic therapy. In situations where only one or a few joints are active, intra-articular drug…
Abstract Number: 417 • 2017 ACR/ARHP Annual Meeting
Improvement in Overall Work Productivity Among Biologic-NaïVe Patients with Rheumatoid Arthritis Treated with Tocilizumab Subcutaneous Injection: A Prospective, Real World, Observational Study in Japan
Yoshiya Tanaka¹, Hideto Kameda², Kazuyoshi Saito³, Yuko Kaneko⁴, Eiichi Tanaka⁵, Shinsuke Yasuda⁶, Naoto Tamura⁷, Keishi Fujio⁸, Takao Fujii⁹, Toshihisa Kojima¹⁰, Tatsuhiko Anzai¹¹, Chikuma Hamada¹², Yoshihisa Fujino¹³, Shinya Matsuda¹³ and Hitoshi Kohsaka¹⁴, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ²Division of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Tokyo, Japan, ³Tobata General Hospital, Fukuoka, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁵Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁶Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ⁷Department of Internal Medicine and Rheumatology, Juntedo University School of Medicine, Tokyo, Japan, ⁸Department of Allergy and Rheumatology, The University of Tokyo, Tokyo, Japan, ⁹Department of Rheumatism and Collagen Disease, Wakayama Medical University, Wakayama, Japan, ¹⁰Nagoya Univ. Grad. Schl. of Med., Nagoya, Japan, ¹¹Data Science Division, Statistics Analysis Department 1, EPS Corporation, Tokyo, Japan, ¹²Department of Information and Computer Technology, Tokyo University of Science, Tokyo, Japan, ¹³Department of Preventive Medicine and Community Health, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ¹⁴Department of Rheumatology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
Background/Purpose: This is the first study assessing the effect of subcutaneous tocilizumab (TCZ-SC) and/or conventional synthetic DMARDs (csDMARDs) on work productivity and activity impairment (WPAI)…
Abstract Number: 1651 • 2016 ACR/ARHP Annual Meeting
A Case Series on Patients on Tofacitinib in Combination with a Biologic
Nashla Barroso¹ and Daniel E. Furst², ¹Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Although there have been significant advances in the treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA). patients can experience a lack of or…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].